Status:
COMPLETED
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
Lead Sponsor:
Ullevaal University Hospital
Collaborating Sponsors:
Schering-Plough
Conditions:
Hepatitis C Virus Infection
Eligibility:
MALE
18-70 years
Phase:
PHASE3
Brief Summary
Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there is no important diffe...
Detailed Description
Patients with HCV genotype 2 or 3 infection are currently recommended 6 months treatment with pegylated interferon alfa (2a or 2b) and ribavirin.Approximately 80% obtain sustained virological response...
Eligibility Criteria
Inclusion
- HCV RNA positive Genotype 2 or 3 Treatment naive Raised ALT
- \-
Exclusion
- Active substance abuse Poorly controlled psychiatric disease Decompensated cirrhosis HBsAg positive Anti-HIV positive Suffering from other significant concurrent medical conditions including chronic liver diseases -
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
435 Patients enrolled
Trial Details
Trial ID
NCT00308048
Start Date
March 1 2004
End Date
September 1 2006
Last Update
July 6 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ullevaal University Hospital
Oslo, Norway, 0407